// App-Quantinova.ai

1000 : Joint Analysis of the ABC (Anthracyclines in Early Breast Cancer) Trials (USOR 06-090, NSABP B-46I/USOR 07132, NSABP B-49 [NRG Oncology]) Comparing Docetaxel Plus Cyclophosphamide (TC) to Anthracycline/Taxane-Based Chemotherapy Regimens (TaxAC) in Women with High-Risk, HER2-Negative Breast Cancer

Researchers

Presenter

  • Joanne Lorraine Blum

Principal Investigators

  • Greg Yothers

  • Lina Asmar

  • Charles E. Geyer

  • Samuel A. Jacobs

  • Nicholas J. Robert

  • James Norman Atkins

  • Joyce O'Shaughnessy

  • Chau T. Dang

  • Henry Leonidas Gomez

  • Louis Fehrenbacher

  • Svetislava J. Vukelja

  • Alan P. Lyss

  • Devchand Paul

  • Adam M. Brufsky

  • Sandra M. Swain

  • Eleftherios P. Mamounas

  • Stephen E. Jones

  • Norman Wolmark

Medical Centers

  • US Oncology Research, and Texas Oncology - Baylor Charles A. Sammons Cancer Center, Dallas, TX

  • NSABP/NRG Oncology, and US Oncology Research, and Metro-Minnesota Community Oncology Research Consotrium (MMCORC), Minneapolis, MN

  • NRG Oncology, and The University of Pittsburgh, Pittsburgh, PA

  • US Oncology Research, and McKesson Specialty Health, The Woodlands, TX

  • NSABP/NRG Oncology, and The Massey Cancer Center, Virginia Commonwealth University, Pittsburgh, PA

  • NSABP/NRG Oncology, and The University of Pittsburgh Cancer Institute, University of Pittsburgh School of Medicine, Pittsburgh, PA

  • The US Oncology Network, Fairfax, VA

  • NSABP/NRG Oncology, and The Southeastern Medical Oncology Center, Goldsboro, NC

  • US Oncology Research, and The Baylor University Medical Center, Dallas, TX

  • Memorial Sloan Kettering Cancer Center, Port Washington, NY

  • ECOG/ACRIN, and The Instituto Nacional de Enfermedades Neoplasicas INEN, Lima, Peru

  • NSABP/NRG Oncology, and Kaiser Permanente Northern California, Novato, CA

  • US Oncology Research, and Texas Oncology - Tyler Cancer Center, Tyler, TX

  • NSABP/NRG Oncology, and The Heartland Cancer Research NCORP/Missouri Baptist Cancer Center, St. Louis, MO

  • US Oncology Research, and Rocky Mountain Cancer Centers, Denver, CO

  • NSABP/NRG Oncology, and The Magee Womens Hospital, UPMC, Pittsburgh, PA

  • NSABP/NRG Oncology, and The Washington Cancer Institute, MedStar Washington Hospital Center, Washington, DC

  • NSABP/NRG Oncology, and UF Cancer Center at Orlando Health, Orlando, FL

  • US Oncology Research, and The Woodlands, The Woodlands, TX

  • NSABP/NRG Oncology, and The Allegheny Cancer Center at Allegheny General Hospital, Pittsburgh, PA

Locations

  • United States

  • Peru

Companies

  • NCI Community Oncolo

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Breast cancer

Biomarkers

  • N/A

Drug/Treatment

  • Cyclophosphamide

  • Cyclophosphamide Injection

  • Docetaxel

  • taxane

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • NCT01547741

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved